IFLR1000

BeiGene HKEX IPO

8/8/2018
IPO
Select tab

Announced

8/8/2018

Overview:

Daniel Semerdzhiev - Data analyst

Jurisdictions:

Cayman Islands
Hong Kong SAR

Deal type:

IPO

Practice area:

Capital markets : Equity

Governing law:

Hong Kong

Industry sector:

Pharmaceuticals and life sciences

Firms:
Davis Polk & Wardwell

Party: Morgan Stanley Asia (Underwriter)

Party: Goldman Sachs (Underwriter)

Party: Credit Suisse Hong Kong (Underwriter)

Party: China International Capital Corporation Hong Kong Securities (Underwriter)

Party: Deutsche Bank AG Na ON (Underwriter)

Party: UBS AG (Underwriter)

Party: China Renaissance Securities (Underwriter)

Fangda Partners

Party: BeiGene Ltd (Issuer)

JunHe

Party: Credit Suisse Hong Kong (Underwriter)

Party: China International Capital Corporation Hong Kong Securities (Underwriter)

Party: Deutsche Bank AG Na ON (Underwriter)

Party: UBS AG (Underwriter)

Party: China Renaissance Securities (Underwriter)

Party: Morgan Stanley Asia (Underwriter)

Party: Goldman Sachs (Underwriter)

Mourant Ozannes

Party: BeiGene Ltd (Issuer)

Skadden Arps Slate Meagher & Flom

Party: BeiGene Ltd (Issuer)

Sullivan & Cromwell

Party: BeiGene's exising shareholder (Shareholder)

Related deals